The company
Adicet Bio, Inc.
ACET · Nasdaq
ACET stood above a rising 150-day average in 9 of the last 52 weekly readings, and has been out of that trend for the last 4 weeks. It is 43.4% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−12 points in four weeks); Health Care: 28% (−6 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 4
- Industry in uptrend
- 18% -12 in 4 wk
- Insider buys, 12 months
- $3.2M
- Insider sales, 12 months
- $1.3M
- Officials’ trades on record
- 0
- Institutions holding
- 54 (+11)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 9 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Orbimed Advisors Llc10% owner | sold | 32,523at $6.29 | 8 Apr 2026filed 9 Apr 2026 |
| Orbimed Advisors Llc10% owner | sold | 40,416at $6.52 | 8 Apr 2026filed 9 Apr 2026 |
| Orbimed Advisors Llc10% owner | sold | 29,319at $6.53 | 7 Apr 2026filed 9 Apr 2026 |
| Orbimed Advisors Llc10% owner | sold | 2,400at $6.38 | 7 Apr 2026filed 9 Apr 2026 |
| Ra Capital Management, L.p.10% owner | bought | 74,751at $7.27 | 20 Feb 2026filed 13 Apr 2026 |
| Ra Capital Management, L.p.10% owner | bought | 74,268at $7.21 | 19 Feb 2026filed 13 Apr 2026 |
| Ra Capital Management, L.p.10% owner | bought | 74,577at $7.04 | 18 Feb 2026filed 13 Apr 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P.reduced · filed 14 Aug 2026 | 932,624$8.1M | -250,000−21.1% |
| ORBIMED ADVISORS LLCreduced · filed 14 Aug 2026 | 844,787$7.3M | -183,157−17.8% |
| FRANKLIN RESOURCES INCunchanged · filed 13 Aug 2026 | 626,571$5.4M | 00.0% |
| CITADEL ADVISORS LLCadded · filed 14 Aug 2026 | 432,738$3.7M | +50,915+13.3% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 343,228$3.0M | +6,704+2.0% |
| ADAGE CAPITAL PARTNERS GP, L.L.C.unchanged · filed 14 Aug 2026 | 274,375$2.4M | 00.0% |
| RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026 | 265,945$2.3M | +33,354+14.3% |
| Stonepine Capital Management, LLCadded · filed 14 Aug 2026 | 245,518$2.1M | +23,563+10.6% |
| Alyeska Investment Group, L.P.unchanged · filed 14 Aug 2026 | 203,799$1.8M | 00.0% |
| Schonfeld Strategic Advisors LLCnew · filed 14 Aug 2026 | 195,514$1.7M | +195,514 |
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.